Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Frontiers in MedicineOpen Access

The efficacy and safety of remimazolam for the management of emergence agitation: a randomized, double-blind, placebo-controlled study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaoxing LuMZMeiyan ZhouYLYao Lu

Discussion

Loading...

Member takes

Overview

Randomized controlled trial shows remimazolam improves treatment success in emergence agitation, highlighting its potential benefits over placebo.

Key Points

  • Remimazolam improved treatment success rates significantly, with 85.9% success for 5.0 mg vs. 44.3% for placebo.
  • Patients receiving remimazolam required less rescue propofol and experienced shorter durations of emergence agitation.
  • This randomized controlled trial involved 219 adults post-otolaryngological surgery, with careful monitoring of adverse events.
  • Findings suggest remimazolam offers a balance between efficacy and safety, especially with the 2.5 mg dose for managing emergence agitation.

Cite This Study

Lu et al. (2025) studied this question.

synapsesocial.com/papers/68af31efcf1dd9ea359e830ehttps://doi.org/10.3389/fmed.2025.1612779
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of remimazolam for induction and maintenance of general anesthesia in day surgery: a randomized controlled non-inferiority clinical trial2025
  2. 2Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial2025
  3. 3Evaluation of the Safety and Efficacy of Remimazolam Combined With Remifentanil for Sedation in Adult Dental Anxiety Patients Undergoing Mandibular Impacted Third Molar Extraction: A Single-Center, Retrospective Cohort Analysis2025
  4. 4Rethinking remimazolam: reconciling regulatory positioning with clinical reality2026
  5. 5Remimazolam vs. dexmedetomidine for postoperative sedation in oral tumor patients undergoing free flap reconstruction: a randomized controlled pilot trial2025